Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache-like symptoms, focusing on neck stiffness.
Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache-like symptoms, focusing on neck stiffness.
复制标题
DOI：
10.1007/s10194-005-0249-z
复制
发表时间：
2005-12
影响因子：
7.4
通讯作者：
Takagi, Shigeharu
中科院分区：
文献类型：
--
作者：
Okuma, Hirohisa;Kitagawa, Yasuhisa;Takagi, Shigeharu
据日本流行病学研究显示，紧张性头痛患者多达2200万，偏头痛患者高达840万。此外，同时患有这两种类型头痛的患者估计占头痛患者的50%以上。我们研究了药物治疗对伴有紧张性头痛样症状的偏头痛的疗效，主要关注颈部僵硬。我们通过比较 34 名偏头痛患者治疗前后的结果来评估利扎曲普坦的疗效，其中 16 名无颈部僵硬（无颈部因素的偏头痛：WONF）和 18 名有颈部僵硬的患者（有颈部因素的偏头痛：WNF），这些患者于 2004 年 3 月 1 日至 2005 年 5 月 31 日在我们的神经内科接受治疗。在这项研究中，所有患者都被要求记录他们的偏头痛状态。医生根据国际头痛协会的诊断标准对偏头痛的严重程度进行分类，并据此评估药物疗效。根据 Ferrari 博士的报告，我们在研究中选择利扎曲普坦用于偏头痛治疗。在利扎曲普坦的疗效研究中，在34名偏头痛患者中，治疗后2小时的疼痛缓解率（79.4％）和无痛率（41.2％）与Ferrari等人的荟萃分析中报告的结果一样高，表明利扎曲普坦的疗效很高。 WONF组和WNF组的疗效比较中，无痛率分别为56.3%和27.8%，累积疼痛缓解率分别为100%和61.1%，其中WONF组效果更好。 WONF 组的测试结果也明显更好 (p=0.0076)。利扎曲普坦被证明可有效治疗伴有紧张性头痛样症状的偏头痛患者。比较有和无紧张性头痛样症状的患者组的有效率，发现无颈强直组的疼痛缓解率较高。
According to an epidemiological study in Japan, there are as many as 22 million patients with tension headache and 8.4 million with migraine. Furthermore, patients suffering from both types of headache concurrently are estimated to account for more than 50% of headache patients. We studied the efficacy of drug therapy for migraine accompanied by tension headache–like symptoms, focusing principally on neck stiffness. We evaluated the efficacy of rizatriptan by comparison of findings before and after therapy in 34 migraine patients, consisting of 16 without neck stiffness (migraine without neck factor: WONF) and 18 with it (migraine with neck factor: WNF), who received treatment at our neurology/internal medicine department from 1 March 2004 to 31 May 2005. In the study, all the patients were asked to keep a record of their migraine status. The severity of migraine was classified by physicians according to the International Headache Society diagnostic criteria, based on which drug efficacy was evaluated. We selected rizatriptan for migraine treatment in our study based on Dr. Ferrari’s report. In the efficacy study of rizatriptan, in the group of 34 migraine patients, the pain relief rate (79.4%) and pain–free rate (41.2%) at two hours after treatment were as high as those reported in the meta–analysis performed by Ferrari et al., indicating high efficacy of rizatriptan. In the efficacy comparison between the WONF and WNF groups, the painfree rates were 56.3% and 27.8%, and cumulative pain relief rates were 100% and 61.1%, respectively, with better results in the WONF group. A test result was also significantly better (p=0.0076) in the WONF group. Rizatriptan was proved effective in treating migraine patients accompanied by tension headachelike symptoms. Comparison of efficacy rates between patient groups with and without tension headache–like symptoms showed that the pain relief rate in the group without neck stiffness was higher.